RE: Val 4016 Jan 2019 10:18
RayPointer This is an extract from a publication middle of last year: "We initially proposed entry directly into a single, multi-national, 200-patient trial, in order to achieve sufficient data to request market authorisation. However, on consultation with the regulatory authorities, we decided to run the pilot study first with a small handful of patients to check for surprise results."